Ian Wilding will receive the 2005 Career Achievement in Oral Drug Delivery Award, sponsored by the Controlled Release Society (CRS) and Eurand
One of Pharmaceutical Profiles's founders Ian Wilding is to be honoured at this year's Controlled Release Society Annual Meeting (18-22 June 2005, Miami Beach, Florida) with a major career achievement award.
Wilding will receive the 2005 Career Achievement in Oral Drug Delivery Award, sponsored by the Controlled Release Society (CRS) and Eurand.
The CRS is an international organisation which serves 3000 members in more than 50 countries.
The organisation is dedicated to improving the quality of life by advancing science, technology and education in the field of controlled delivery of bioactive substances.
Jennifer Dressman of the Controlled Release Society explained: "As an industry leader, Dr Wilding has demonstrated innovation in the field of oral drug delivery throughout his career and the Eurand Award Committee was delighted to honour him in this way".
It will be a busy event for Wilding and the company.
As well as receiving his award, Wilding will be speaking in the event's Pearls of Wisdom session, chairing two podium presentation sessions, and taking part in a further event workshop.
Early phase drug development specialist Pharmaceutical Profiles will also have a stand at the associated exposition.
Wilding received his first class honours degree in pharmacy from the University of Nottingham in 1984 and his PhD from the same university in 1990.
He has published over 230 research papers/abstracts and has supervised a number of PhD students in the area of biopharmaceutics at Nottingham University.
In addition, he is a special Professor in the Institute of Pharmaceutical Sciences at Nottingham University.
He is a frequent speaker at international meetings and is a respected authority on drug delivery and intestinal absorption, says the company.
In 1997 he served as an expert scientist for the FDA in the area of food effects on drug bioavailability and is currently the only non-American scientist working with PQRI examining US regulatory guidance in the area of oral biopharmaceutics.
He is a member of the UK CBI's Technology and Innovation Committee and a Director of BioCity, Nottingham, one of Europe's largest bioscience incubators.
Wilding also steered Pharmaceutical Profiles to its current status as a world renowned specialist in early phase drug development which now carries out projects for most of the world's major pharmaceutical and biotechnology organisations using innovative technologies, such as the Enterion drug delivery capsule, and sophisticated medical imaging modalities.
The company underwent a successful MBO in January 2005.
